Home » Stocks » GBLX

GB Sciences, Inc. (GBLX)

Stock Price: $0.0489 USD -0.0011 (-2.20%)
Updated Jun 23, 2021 3:32 PM EDT - Market closed
Market Cap 14.35M
Revenue (ttm) 1.34M
Net Income (ttm) -11.87M
Shares Out 280.97M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 23
Last Price $0.0489
Previous Close $0.0500
Change ($) -0.0011
Change (%) -2.20%
Day's Open 0.0510
Day's Range 0.0436 - 0.0520
Day's Volume 158,535
52-Week Range 0.0250 - 0.1300

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The UWC also retains John Poss as Chairman and CEO of GB Sciences, Inc.  LAS VEGAS, NV / ACCESSWIRE / June 17, 2021 / Dr. Andrea Small-Howard has been promoted to the role of President of GB Sciences, I...

1 week ago - Accesswire

Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM). LAS VEGAS, NV / ACCESSWIRE / April 20, 2021 / GB Sciences, Inc. (...

2 months ago - Accesswire

GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ab...

2 months ago - Accesswire

LAS VEGAS, NV / ACCESSWIRE / March 23, 2021 / GB Sciences, Inc. (OTCQB:GBLX) and its Spanish research partners at the Universidad de Sevilla (USE) are pleased to announce the publication of a new scient...

3 months ago - Accesswire

LAS VEGAS, NV / ACCESSWIRE / January 12, 2021 / GB Sciences, Inc. (OTCQB:GBLX) completed the sale of its remaining interest in GB Sciences Louisiana LLC ("GBSLA") on December 16, 2020. In November 2019,...

5 months ago - Accesswire

About GBLX

GB Sciences, Inc. engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

Industry
Biotechnology
CEO
John Poss
Employees
23
Stock Exchange
OTCMKTS
Ticker Symbol
GBLX
Full Company Profile

Financial Performance

In 2019, GB Sciences's revenue was $3.12 million, a decrease of -9.67% compared to the previous year's $3.45 million. Losses were -$12.37 million, -47.69% less than in 2018.

Financial Statements